Tobacco company Altria Group Inc (NYSE: MO)'s third-quarter print was viewed favorably by at least two Street analysts.
Deutsche Bank analyst Steve Powers maintained at Buy, price target lowered from $60 to $58.
BofA: Vaping Crackdown Could Benefit Cigarette Manufacturers
Altria maintained its 2019 guidance of EPS growth of 5-7% and announced its second IQOS store in Atlanta, along with plans for new locations, Lewandowski said in a Friday note.
The company's investments will likely be disciplined and quick to support new markets and longer-term growth, the analyst said.
Altria also announced a $4.5-billion impairment charge related to its investment in Juul ahead of what could prove to be a smaller vaping market, she said.
This could be a positive for big tobacco companies like Altria as users return to cigarettes to satisfy their nicotine fix, Lewandowski said.
Altria remains best-positioned within the market given its "total tobacco strategy" coupled with its ability to be flexible and adaptive to market changes, according to BofA.
Deutsche Bank: Q3 Better Than Expected
Investors should have a favorable reaction to Altria's earnings report, which was highlighted by better-than-expected performance across smokeable volume, total revenue, total EBIT and EPS, Powers said.
On the other hand, cigarette shipments were down in the quarter, but Marlboro's decline of 6% was at a slower rate than other brands, which supported a "robust" price/mix delivery of positive nine points, the analyst said.
Altria's $4.5-billion Juul writedown is a negative in "absolute terms," but marks an event that was likely anticipated given the public challenges Juul faces, according to Deutsche Bank.
Altria shares were trading 0.83% higher at $45.16 at the time of publication Friday.
Altria Takes .5B Writedown On Juul Investment
Altria Group Reports Q3 Earnings Beat, Reaffirms Guidance
Latest Ratings for MO
View More Analyst Ratings for MO
View the Latest Analyst Ratings
See more from Benzinga
- Altria Takes .5B Writedown On Juul Investment
- Ex-FDA Chief: Juul Created Teen Vaping Epidemic
- Cronos CEO Talks Vaping With Cramer
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.